Justin Hanes, Ph.D.

Justin Hanes is a VenturePartner & the Chief Scientist at Catalio Capital Management, LP.

Director, Center of Nanomedicine at Johns Hopkins Medicine

Nanomedicine

EDUCATION
BS – University of California Los Angeles
PhD – Massachusetts Institute of Technology

AWARDS AND ACCOLADES
National Academy of Inventors
The World’s Most Influential Scientific Minds / Highly Cited Researcher” by Thompson Reuters
MIT Technology Review 35 Innovators Under 35

COMPANIES AND BOARDS
Co-Founder – Kala Pharmaceuticals (NASDAQ: KALA), GrayBug Vision, Ashvattha Therapeutics, Orpheris, Theraly Fibrosis, Neuraly, Spiral Therapeutics, Advanced Inhalation Research (acquired by Alkermes), Civitas Therapeutics (acquired by Acorda)

MEMBER OF Investment Committee

Associated Portfolio Companies

Ashvattha Therapeutics
Orpheris
Perfuse Therapeutics
Spiral Therapeutics